Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

THE AMAZING NEUROPEPTIDE and cancer———

The VIP antagonist is a hybrid peptide consisting of a portion of VIP and a portion of neurotensin, designed to change the membrane permeability of the VIP portion. The hybrid antagonist displaced 80 to 90% of [125I]VIP binding to cell cultures from cerebral cortex, hippocampus or spinal cord.

https://pubmed.ncbi.nlm.nih.gov/1646331/

The most prevalent lung cancer, non-small cell lung cancer (NSCLC) has receptors for vasoactive intestinal peptide (VIP). Here the effects of a VIP antagonist (VIP-hyb) on NSCLC growth were investigated.

https://pubmed.ncbi.nlm.nih.gov/8389448/


Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo ———

Kaname Maruno, Afaf Absood, and Sami I. Said

https://www.pnas.org/content/95/24/14373